Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Formula 3 is a topical antifungal solution developed by Tetra Corporation for the treatment of athlete's foot (tinea pedis) and ringworm. The product's active ingredient is 1% tolnaftate, a small molecule antifungal agent that has been FDA-approved for over 50 years. Formula 3 utilizes a patented technology that renders tolnaftate oil-soluble by using natural jojoba oil as the delivery vehicle. This in-solution formulation prevents the active ingredient from separating and facilitates rapid absorption into the skin, delivering the antifungal agent directly to the site of infection. It works by inhibiting the growth of dermatophyte fungi. Formula 3 is an over-the-counter (OTC) product and has received the American Podiatric Medical Association's Seal of Approval.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Formula 3.